CTRI/2014/11/005204已完成4 期
An Open Label, Parallel, Randomized Study to Evaluate the pharmacokinetics, Safety and Efficacy at three doses of Nanosomal Docetaxel Lipid Suspension for Injection in Locally Advanced or Metastatic Breast Cancer Patients after failure of prior chemotherapy. - NA
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •1.The patient willing to give written signed and dated informed consent to participate in the study.
- •2.Female >=18 years and <=65 years of age.
- •3.Patient must have histopathologically /cytologically confirmed breast cancer.
- •4.Patient must have locally advanced or metastatic breast cancer after failure of chemotherapy. Prior chemotherapy should have included an anthracycline unless clinically contraindicated
- •5.Have at least one measurable lesion as per the RECIST criteria (version 1.1).
- •6.Eastern Cooperative Oncology Group (ECOG) performance status <= 2
- •7.Left Ventricular Ejection fraction (LVEF) >= 50% as per Echocardiography (ECHO).
- •8.Patient must have recovered from any toxic effects of previous chemotherapy or radiotherapy as judged by the Investigator.
- •9.Previous chemotherapy/radiotherapy should be completed 4 weeks prior to start of IMP administration.
- •10.Patients with life expectancy of at least 6 months.
- •11.Serum pregnancy test at screening and urine pregnancy test on Day 1(before randomization) must be negative.
- •12.Sexually active women, unless surgically sterile (at least 6 months prior to Study drug administration) or postmenopausal for at least 12 consecutive months, must use an effective method of avoiding pregnancy (including oral, transdermal, or implanted contraceptives [any hormonal method in conjunction with a secondary method], intrauterine device, female condom with spermicide, diaphragm with spermicide, absolute sexual abstinence, use of condom with spermicide by sexual partner or sterile [at least 6 months prior to Study drug administration] for at least 4 weeks prior to study drug administration, during study and up to 30 days after the last dose of study drug. Cessation of birth control after this point should be discussed with a responsible physician. (It is investigatorâ??s responsibility to ensure that above points regarding an effective method of avoiding pregnancy are discussed with patient in detail and patient agreed for this and it is documented in source document. The investigator should ensure that the patient is using an effective method of avoiding pregnancy as per protocol).
- •13.Patient with adequate bone marrow, renal and hepatic function.
排除标准
- •1.Patient who has a history of hypersensitivity reactions to docetaxel or any other component of formulation or to any drugs formulated with polysorbate 80.
- •2.Patients with HER2+ status
- •3.Patient who is already exposed to docetaxel injection.
- •4.Any of the following cardiac conditions:
- •a.Unstable angina
- •b.Myocardial infarction within the past 6
- •c.Severe uncontrolled ventricular arrhythmias
- •d.Clinically significant pericardial disease
- •e.Electrocardiographic evidence of acute
- •f.Patient with evidence of abnormal cardiac
- •conduction (e.g., bundle branch block or
- •heart block) except in whom the disease
- •has been stable for the past six months
- •g.History of cardiac disease that met the
- •NYHA Classification class 2 or greater.
- •5.Uncontrolled diabetes or infection.
- •6.Known history of drug addiction within last 1 year.
- •7.Patients with known CNS lesions (brain metastasis or carcinomatous meningitis).
- •8.The receipt of an investigational medicinal product or participation in other drug research study within a period of 30 days prior to the first dose of investigational medicinal Product for the current study.
- •9.Pre-existing motor or sensory neurotoxicity of a severity >= grade 2 as defined by NCI CTCAE 4.03 criteria.
- •10.Known case of HIV infection.
- •11.Any other condition that, in the investigatorâ??s judgment, might increase the risk to the patient or decrease the chance of obtaining satisfactory data needed to achieve the objectives of the study.
- •12.Patients who are unwilling or unable to follow protocol requirements.
研究者
相似试验
尚未招募
4 期
A clinical trial to study and compare the effectiveness and safety of Eberconazole 1% cream and Terbinafine 1% cream in patients with Tinea versicolorCTRI/2019/11/021907Dr Nidarsan Viswanathan
进行中（未招募）
1 期
Study to compare umeclidinium with glycopyrronium in COPD subjectsMedDRA version: 17.1Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersChronic Obstructive Pulmonary DiseaseEUCTR2014-000885-23-DEGlaxoSmithKline Research and Development1,006
进行中（未招募）
不适用
Study to compare umeclidinium with glycopyrronium in COPD subjectsChronic Obstructive Pulmonary DiseaseEUCTR2014-000885-23-SEGlaxoSmithKline Research and Development1,006
进行中（未招募）
不适用
Study to compare umeclidinium with glycopyrronium in COPD subjectsChronic Obstructive Pulmonary DiseaseEUCTR2014-000885-23-HUGlaxoSmithKline Research and Development1,006
进行中（未招募）
不适用
A 12-Week study to compare Umeclidinium (UMEC) 62.5 mcg and Glycopyrronium 44 mcg in COPD Patients.Chronic Obstructive Pulmonary Disease (COPD)MedDRA version: 17.0Level: PTClassification code 10009033Term: Chronic obstructive pulmonary diseaseSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-000885-23-ESGlaxoSmithKline, S.A.1,006